Page last updated: 2024-11-12
eristostatin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
eristostatin: disintegrin from venom of Eristocophis macmahoin; inhibits platelet thromboembolism & protects animal from sudden death [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 16132436 |
MeSH ID | M0223473 |
Synonyms (3)
Synonym |
---|
132051-67-3 |
eristostatin |
DTXSID20157328 |
Research Excerpts
Treatment
All eristostatin-treated cells healed less of the wounded area than control conditions. Eristostatin treatment did not prevent extravasation, and the timing and process was similar for both treated and control cells.
Excerpt | Reference | Relevance |
---|---|---|
"All eristostatin-treated cells healed less of the wounded area than control conditions." | ( Scratching below the surface: wound healing and alanine mutagenesis provide unique insights into interactions between eristostatin, platelets and melanoma cells. Hensley, B; McLane, MA; Paquette-Straub, C; Srivastava, A; Tian, J; Zelinskas, C; Zhang, X, 2005) | 1.02 |
"Eristostatin treatment did not prevent extravasation, and the timing and process of extravasation were similar for both treated and control cells; by 3-4 days p.i." | ( Effects of the disintegrin eristostatin on individual steps of hematogenous metastasis. Chambers, AF; Grattan, M; Groom, AC; Khokha, R; Koop, S; MacDonald, IC; McLane, MA; Morris, VL; Niewiarowski, S; Schmidt, EE, 1995) | 1.31 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (17)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 11 (64.71) | 18.2507 |
2000's | 5 (29.41) | 29.6817 |
2010's | 1 (5.88) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.16
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.16) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 19 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |